GastroAGI Logo
OverviewBlogsAbout
Trending TopicsDaily BriefConference
Topics/Cirrhosis Liver/Cirrhosis Care Should Become a Preventive Bundle—not a Series of Rescue Interventions: AJG | October 2026
4

Cirrhosis Care Should Become a Preventive Bundle—not a Series of Rescue Interventions: AJG | October 2026

Clinical knowledge base written and curated by GastroAGI Team from primary medical literatureLast updated October 1, 2026

What Did the Guideline Find?

The new ACG guideline translates preventive cirrhosis care into 18 GRADE-assessed recommendations and six key concepts spanning cirrhosis-specific complications, infection prevention, lifestyle interventions and non-hepatic comorbidities. Strong recommendations include six-monthly hepatocellular carcinoma surveillance, hepatitis A testing and vaccination when nonimmune, indicated influenza, COVID-19 and respiratory syncytial virus vaccination, smoking-cessation counselling, and carvedilol or endoscopic ligation for high-risk oesophageal varices.

Conditional recommendations include lactulose for minimal hepatic encephalopathy, adjunctive rifaximin following hospitalisation, short-course antibiotic prophylaxis during upper-GI bleeding, structured treatment for alcohol-use disorder after discharge, dietitian-led nutritional care, supervised exercise and bisphosphonates for osteoporosis. Importantly, most recommendations rest on low-certainty evidence despite their clinical plausibility and established preventive value. gi.org

Why Does It Matter?

The guideline supports using a structured checklist at every cirrhosis visit rather than waiting for decompensation. Vaccination, cancer surveillance, bone health, nutrition, alcohol treatment and cognitive assessment should be treated as core hepatology—not ancillary primary care.

GastroAGI Takeaway

Build a cirrhosis prevention bundle into every clinic visit: surveillance, vaccination, cognition, nutrition, lifestyle and bone health are disease-modifying care.

Related Q&A

05

TIPS Beyond Conventional Indications: Encouraging Data in HRS-AKI, but Patient Selection Remains Critical: Scientific Reports | September 2026

What Did the Study Find? This multicenter Asia-Pacific study evaluated 207 patients undergoing technically successful TIPS across six centres, including high-risk populations with HRS-AKI, CKD and ACLF. s41598-026-70413-9_reference...

06

Portal Vein Thrombosis in Cirrhosis: A Marker of Higher Short-Term Mortality: Liver Transplantation | September 2026

What Did the Study Find? The multinational CLEARED Consortium prospectively evaluated 7,721 non-electively hospitalised patients with cirrhosis, providing large-scale global data on portal vein thrombosis (PVT). PVT was...

07

Beyond West Haven: Can mHEST Make Hepatic Encephalopathy Staging More Objective?: CGH | September 2026

What Did the Study Find? The study evaluated the modified Hepatic Encephalopathy Staging Tool (mHEST) as a more objective alternative to conventional West Haven criteria. Among 49 clinicians...

08

Recombinant Albumin in Cirrhosis: Can We Move Beyond Donor Plasma?: Signal Transduction and Targeted Therapy | September 2026

What Did the Study Find? This phase III trial randomized 390 patients with cirrhotic ascites and hypoalbuminemia to recombinant human serum albumin (rHSA) or conventional plasma-derived albumin. Both...

09

Preventing Falls in Cirrhosis: Lactulose + TeleTai-Chi in LiveSMART Trial: Hepatology | September 2026

What Did the Study Find? The peer-reviewed LiveSMART trial evaluated lactulose and TeleTai-Chi in patients with cirrhosis and portal hypertension without previous overt hepatic encephalopathy (HE). Lactulose followed...

10

High-Risk ACLF: Should Antifungal Therapy Start Before Infection Is Proven?: AJG | September 2026

What Did the Study Find? This pragmatic RCT randomized 216 hospitalized patients with ACLF and predefined risk factors for invasive fungal infection (IFI) to immediate empirical antifungal therapy...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer